| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-82,764 | -114,780 | -74,356 | -54,890 | -46,964 | - | |
Net loss | ||||||
- | - | - | - | - | -14,222 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Non-cash other income/expense, net | ||||||
40 | -362 | 1,371 | -996 | -144 | -663 | |
Non-cash interest income | ||||||
-22 | -45 | - | 52 | 1 | - | |
Non-cash interest expense | ||||||
519 | -104 | - | 35 | 21,465 | 1,892 | |
Depreciation and amortization expense | ||||||
396 | 510 | 432 | 233 | 153 | 166 | |
Amortization of right-of-use assets | ||||||
374 | - | - | - | - | - | |
Stock-based compensation | ||||||
9,748 | 5,154 | 5,732 | 2,545 | 1,351 | 96 | |
In-process research and development in connection with acquisition | ||||||
- | 32,048 | - | - | - | - | |
Deferred income taxes | ||||||
- | - | 1,410 | -794 | -627 | 11 | |
Other, net | ||||||
48 | 14 | 131 | 1 | -5 | 1 | |
Changes in operating assets and liabilities: | ||||||
Increase in long-term receivables | ||||||
-50 | 3 | 5 | -10 | 71 | 38 | |
Increase in accounts receivable, net and other receivables and prepaid expenses | ||||||
-2,582 | -1,139 | 223 | - | - | - | |
Increase in inventory | ||||||
682 | - | - | - | - | - | |
Changes in other receivables | ||||||
- | - | - | 1,932 | 3,181 | 647 | |
Increase/(decrease) in accounts payable | ||||||
1,310 | -2,969 | 2,585 | -383 | 2,651 | -118 | |
Decrease in accrued expenses and other liabilities | ||||||
-3,209 | 5,742 | -3,778 | 6,034 | 3,971 | 684 | |
Increase/(decrease) in other non-current liabilities | ||||||
-172 | 61 | 96 | 24 | 9 | 27 | |
Increase/(decrease) in income tax liabilities | ||||||
-74 | 58 | -1 | -152 | -753 | 78 | |
Net cash used in operating activities | ||||||
-71,892 | -72,723 | -69,348 | -48,325 | -21,858 | - | |
Cash flows from investing activities | ||||||
Net cash used in operating activities | ||||||
- | - | - | - | - | -11,407 | |
Purchases of plant and equipment and intangible assets | ||||||
61 | 229 | 1,173 | 603 | 216 | 90 | |
Purchases of available-for-sale securities | ||||||
- | - | - | 57,035 | - | - | |
Purchases of term deposits | ||||||
- | 115 | 30 | 10 | - | - | |
Changes in restricted cash | ||||||
-392 | - | - | - | - | - | |
Purchases of available-for-sale securities | ||||||
- | - | - | - | 30,603 | - | |
Purchases of term deposits | ||||||
- | - | - | - | 45,885 | - | |
Proceeds from sale of property, plant and equipment | ||||||
- | - | 2 | - | - | 3 | |
Proceeds from maturities of term deposits | ||||||
- | - | - | 45,000 | - | - | |
Proceeds from sales of available-for-sale securities | ||||||
- | - | - | 36,000 | - | - | |
Transaction costs related to Zavante acquisition, net of cash acquired | ||||||
- | 4,260 | -50,950 | - | - | - | |
Net cash used in investing activities | ||||||
331 | -4,604 | 49,749 | 23,352 | -76,704 | - | |
Cash flows from financing activities | ||||||
Proceeds from equity offerings and warrants | ||||||
20,138 | 50,000 | 80,000 | - | - | - | |
Proceeds from at-the-market facility | ||||||
27,944 | 24,219 | - | - | - | - | |
Net cash provided by investing activities | ||||||
- | - | - | - | - | -87 | |
Proceeds from initial public offering | ||||||
- | - | - | - | 106,088 | - | |
Proceeds from December 2016 financing | ||||||
- | - | - | 24,822 | 44,836 | - | |
Other proceeds from shareholders | ||||||
- | - | - | - | 29 | - | |
Proceeds from silent partnership | ||||||
- | - | - | - | 943 | 536 | |
Proceeds from long-term debt, net of issuance costs | ||||||
9,980 | 23,545 | 228 | - | - | - | |
Proceeds from long-term borrowings | ||||||
- | - | - | - | - | 6,171 | |
Proceeds from exercise of stock options | ||||||
- | - | 83 | 269 | 5 | - | |
Proceeds from employee share purchase plan | ||||||
372 | - | - | - | - | - | |
Proceeds from convertible loans | ||||||
- | - | - | - | 3,436 | 4,716 | |
Repayments of participation rights | ||||||
- | - | - | - | 6 | - | |
Repayments of long-term borrowings | ||||||
- | - | - | - | 7,383 | 2,325 | |
Equity transaction costs | ||||||
2,359 | 4,841 | 8,092 | 2,790 | 14,930 | - | |
Net cash provided by (used in) financing activities | ||||||
56,075 | 92,923 | 72,219 | 22,301 | 133,018 | - | |
Effects of foreign currency translation on cash and cash equivalents | ||||||
-106 | -362 | 1,371 | -996 | - | - | |
Net decrease in cash, cash equivalents and restricted cash | ||||||
-15,592 | 15,234 | 53,991 | -3,668 | - | - | |
Effects of foreign currency translation on cash and cash equivalents | ||||||
- | - | - | - | -160 | - | |
Net cash provided by (used in) financing activities | ||||||
- | - | - | - | - | 9,098 | |
Effects of foreign currency translation on cash and cash equivalents | ||||||
- | - | - | - | - | -411 | |
Net (decrease) increase in cash and cash equivalents | ||||||
- | - | - | - | 34,296 | -2,807 | |
Supplemental disclosure of cash flow information: | ||||||
Interest paid | ||||||
2,560 | 7 | 1 | 41 | 1,057 | - | |
Taxes paid | ||||||
11 | 4 | 5 | 867 | 939 | - | |
Equity transaction costs included in accounts payable and accrued expenses | ||||||
555 | 120 | 28 | 1,451 | - | - | |
Interest paid | ||||||
- | - | - | - | - | 553 | |
Taxes paid | ||||||
- | - | - | - | - | 5 | |